News >

Risk Patterns Prior to Progression From MGUS to Myeloma Call for Annual Assessments

Caroline Seymour
Published: Friday, Sep 20, 2019

C. Ola Landgren, MD, PhD

C. Ola Landgren, MD, PhD
Serial assessment of blood-based immune markers showed that the risk of progression from monoclonal gammopathy of undetermined significance (MGUS), the precursor disease to multiple myeloma is fluctuating rather than determinate, and these patients can experience progression to myeloma within 5 years, according to results of a study published in JAMA Oncology.1

“This finding has direct clinical relevance and supports annual blood tests for all individuals diagnosed with MGUS or light-chain MGUS, and, importantly, yearly reassessment of a patient's clinical-risk status,” said Landgren. “Based on our new data, we have already expanded our research program on multiple myeloma and its precursor disease to focus on genomic evolution and characterization of the bone marrow microenvironment. This will help us further understand biological mechanisms of the development of multiple myeloma.”

References

  1. Landgren O, Hofmann J, McShane C, et al. Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma. JAMA Oncol. 2019;5(9):1293-1301. doi:10.1001/jamaoncol.2019.1568.
  2. Cracking a Code: Landmark Prospective Study Helps Researchers Better Understand Which MGUS Patients Will Progress to a Multiple Myeloma Diagnosis. Memorial Sloan Kettering Cancer Center. Published July 18, 2019. https://bit.ly/2kwFDyC. Accessed 3 Aug. 2019

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x